Heart disease and diabetes overlap dangerously
Cardiovascular disease (CVD) — which includes heart attacks, strokes, and heart failure — is the leading cause of death in people with type 2 diabetes. Many of these patients also struggle with obesity. Semaglutide was originally developed to treat type 2 diabetes by helping the pancreas release insulin more effectively. Then it turned out to also cause substantial weight loss.
Large trials like the SELECT trial showed semaglutide reduced major cardiovascular events by about 20% compared to placebo. Most researchers assumed that weight loss was responsible — after all, losing weight is good for the heart.
The surprising twist in the data
But here's where things get interesting. This new study used a massive, de-identified electronic health record (EHR) network covering 29 million U.S. patients, including over 505,000 people who had taken semaglutide. Researchers focused on 47,199 of those patients who had pre-existing cardiovascular disease.
They tracked two things separately: how much semaglutide dose each person achieved, and how much weight each person lost — then compared both factors to heart outcomes measured two to four years later.
Higher drug doses were strongly linked to lower rates of death, heart attack, stroke, and heart failure. But greater weight loss did not show the same consistent, predictable link to better heart outcomes.
Think of it this way: if losing weight were the main driver, you'd expect people who lost the most weight to have the best heart outcomes — regardless of dose. But that's not what the data showed.
The drug itself appears to be doing something directly beneficial for the heart, beyond what the scale reflects.
How semaglutide may act on the heart directly
Semaglutide works by activating a receptor in the body called GLP-1R (glucagon-like peptide-1 receptor). These receptors are found in the pancreas — which is where the drug was designed to work — but researchers found that they also appear significantly in heart cells themselves.
The study used a single-cell gene expression atlas (a detailed map of which genes are active in which cells) to show that GLP-1R is present in cardiomyocytes (the beating muscle cells of the heart), cardiac endothelial cells (which line blood vessels), and certain immune cells in the heart.
This suggests semaglutide may act directly on heart tissue — reducing inflammation, improving how heart cells use energy, or stabilizing blood vessel walls — through mechanisms that have nothing to do with body weight.
Among patients with baseline cardiovascular disease, those who reached the highest doses of semaglutide had roughly 58% lower all-cause mortality risk and about 49% lower risk of combined cardiovascular events (death, heart attack, or stroke) compared to those on lower doses.
In contrast, when researchers grouped patients purely by how much weight they lost — regardless of dose — they found no consistent pattern linking greater weight loss to better heart outcomes.
If you take semaglutide for weight loss or diabetes, this research suggests you should not judge its value only by what the scale says. The cardiovascular protection the drug may offer could be happening independently of weight loss.
This is especially relevant if you have heart disease and your doctor is managing your semaglutide dose. This study suggests that reaching an effective therapeutic dose — not just losing weight — may be the more important goal for heart protection. Talk to your doctor before making any changes, but bring this research to the conversation.
This was an observational study using real-world health records, not a randomized controlled trial. That means it cannot fully rule out confounding factors — things like other medications, lifestyle changes, or underlying health differences that might explain the results. The study also relied on data from a single EHR network and may not represent all patient populations.
These findings are now pushing researchers to design clinical trials that specifically test semaglutide's cardiovascular effects at different doses — independent of weight loss. If future trials confirm that the drug's heart benefits come directly from GLP-1R activation in cardiac tissue, it could open the door to treating heart disease with semaglutide even in people who are not overweight. That would represent a meaningful expansion of how this class of drug is used and understood.
